MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Home・Aktien・Vivani Medical

Vivani Medical

Geschlossen

1.34 19.64

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.28

Max

1.42

Schlüsselkennzahlen
By Trading Economics
Angestellte	37

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+214.96% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-21M 83M
Vorheriger Eröffnungskurs	-18.3
Vorheriger Schlusskurs	1.34

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Jan. 2026, 23:43 UTC

Market Talk

Gold Consolidates; May Face Technical Correction -- Market Talk

20. Jan. 2026, 23:42 UTC

Market Talk

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20. Jan. 2026, 23:41 UTC

Ergebnisse

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20. Jan. 2026, 23:29 UTC

Market Talk

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20. Jan. 2026, 23:26 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Jan. 2026, 23:26 UTC

Market Talk

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20. Jan. 2026, 22:45 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20. Jan. 2026, 22:45 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20. Jan. 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20. Jan. 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20. Jan. 2026, 22:27 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20. Jan. 2026, 22:25 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20. Jan. 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20. Jan. 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20. Jan. 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20. Jan. 2026, 22:18 UTC

Ergebnisse

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20. Jan. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20. Jan. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20. Jan. 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20. Jan. 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20. Jan. 2026, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20. Jan. 2026, 22:11 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20. Jan. 2026, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20. Jan. 2026, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20. Jan. 2026, 22:07 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20. Jan. 2026, 22:06 UTC

Ergebnisse

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20. Jan. 2026, 22:00 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

ESG Roundup: Market Talk

20. Jan. 2026, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

214.96% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 214.96%

Hoch 4 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.